| Literature DB >> 22318204 |
Keiichiro Ishigami1, Masashi Okuro, Yumi Koizumi, Kazuto Satoh, Osamu Iritani, Hiroshi Yano, Toshihiro Higashikawa, Kunimitsu Iwai, Shigeto Morimoto.
Abstract
Pneumonia is one of the most frequent complications in elderly patients with acute ischemic stroke. Although severe hypertension is often observed in the early phase of acute stroke, there are few studies of acute hypertension as a factor influencing the incidence of stroke-associated pneumonia (SAP) in elderly subjects with acute ischemic stroke. To assess the association of acute phase blood-pressure elevation with the incidence of SAP, we compared 10 elderly patients with acute ischemic stroke complicated with severe hypertension (≥ 200/120 mm Hg) with 43 patients with moderate hypertension (160-199/100-119 mm Hg), as well as with 65 control normotensive or mildly hypertensive (<160/100 mm Hg) controls on admission. Data were collected on known risk factors, type of ischemic stroke and underlying chronic conditions. The significance of differences in risk factors was analyzed using univariate and multivariate comparisons of 38 SAP cases and others, 8 SAP death cases and others, and 28 patients with poor outcome associated with in-hospital death or artificial feeding at discharge and others. After adjustment for potential confounding factors, the relative risk estimates for SAP, SAP death and poor outcome were 2.83 (95% confidence interval 1.14-7.05), 5.20 (1.01-26.8) and 6.84 (1.32-35.4), respectively, for severe hypertension relative to normotensive or mildly hypertensive controls. We conclude that severe hypertension on admission is an independent predictive factor for SAP in elderly patients with acute ischemic stroke.Entities:
Mesh:
Year: 2012 PMID: 22318204 PMCID: PMC3368232 DOI: 10.1038/hr.2012.7
Source DB: PubMed Journal: Hypertens Res ISSN: 0916-9636 Impact factor: 3.872
Characteristics of SAP+ and SAP− patients
| n= | n= | P- | |
|---|---|---|---|
| Age (years) | 84.9±5.8 | 84.4±5.2 | 0.518 |
| Male: female | 22:16 | 36:44 | 0.238 |
| Large-artery atherosclerosis: | 17 (44.7) | 45 (56.3) | 0.324 |
| Small-vessel occlusion: | 7 (18.4) | 15 (18.8) | 0.955 |
| Cardiac embolism: | 14 (36.8) | 20 (25.0) | 0.198 |
| BMI (kg m−2) | 19.4±3.0 | 20.0±3.2 | 0.677 |
| SBP (mm Hg) | 166±31 | 150±28 | 0.006 |
| DBP (mm Hg) | 87±17 | 81±19 | 0.066 |
| Pulse pressure (mm Hg) | 80±22 | 69±20 | 0.018 |
| Glasgow Coma Scale | 11.8±3.4 | 13.6±2.6 | 0.001 |
| WBC count ( × 1012 l−1) | 8.13±2.55 | 6.08±1.42 | <0.001 |
| Serum C-reactive protein (mg l−1) | 7.9 (1.5–40.9) | 3.8 (1.0–6.0) | <0.001 |
| Serum albumin (g l−1) | 34.8±4.1 | 35.7±4.5 | 0.189 |
| Dysphagia (%) | 44.7 | 15.0 | 0.001 |
| Past history of stroke (%) | 34.2 | 40.0 | 0.547 |
| Ischemic heart disease (%) | 10.5 | 10.0 | 0.930 |
| Congestive heart failure (%) | 26.3 | 16.3 | 0.199 |
| Chronic kidney disease (%) | 7.9 | 8.8 | 0.877 |
| Diabetes mellitus (%) | 23.7 | 16.3 | 0.335 |
| Hypertension treatment (%) | 26.3 | 23.8 | 0.763 |
| ARB alone (%) | 5.3 | 2.5 | 0.440 |
| ACEI alone (%) | 2.6 | 0 | 0.147 |
| CaB alone (%) | 5.3 | 8.8 | 0.507 |
| Thiazide alone (%) | 0 | 1.3 | 0.491 |
| Two or more antihypertensives (%) | 13.2 | 11.3 | 0.766 |
| ARB with/without others (%) | 13.2 | 10.0 | 0.610 |
| ACEI with/without others (%) | 7.9 | 2.5 | 0.176 |
| CaB with/without others (%) | 7.9 | 16.3 | 0.217 |
| Thiazide with/without others (%) | 10.5 | 5.0 | 0.267 |
Abbreviations: ACEI, angiotensin I-converting enzyme inhibitor; ARB, angiotensin II-receptor blocker; CaB, dihydropiridine calcium-channel blocker; DBP, diastolic blood pressure; SBP, systolic blood pressure.
Results for continuous variables are expressed as mean±s.d. and compared using Mann–Whitney U analysis. Discrete variables are reported as percentages and compared by χ2 analysis.
Characteristics of controls, moderate and severe hypertensives
| n= | n= | n= | P | |
|---|---|---|---|---|
| Age (years) | 84.2±5.8 | 85.5±4.8 | 83.5±5.2 | 0.356 |
| Male: female | 36: 29 | 18: 25 | 4: 6 | 0.329 |
| Large-artery atherosclerosis: | 34 (52.3) | 24 (55.8) | 4 (40.0) | 0.671 |
| Small-vessel occlusion: | 13 (20.0) | 17 (16.3) | 2 (20.0) | 0.885 |
| Cardiac embolism: | 18 (27.7) | 12 (27.9) | 4 (40.0) | 0.722 |
| BMI (kg m−2) | 19.9±3.1 | 20.0±3.2 | 18.1±3.4 | 0.625 |
| SBP (mm Hg) | 133.5±18.4 | 175.0±9.3*** | 210.3±13.9***+++ | <0.001 |
| DBP (mm Hg) | 73.9±14.6 | 90.6±14.9*** | 106.7±17.7***+++ | <0.001 |
| Pulse pressure (mm Hg) | 60.5±15.2 | 83.8±16.5*** | 103.4±12.1***+++ | <0.001 |
| Glasgow Coma Scale | 13.9±3.6 | 11.9±3.6** | 12.2±2.3** | 0.002 |
| WBC ( × 1012 l−1) | 6.47±1.81 | 6.72±2.18 | 8.59±2.59**+ | 0.010 |
| Serum C-reactive protein (mg l−1) | 3.6 (0.8–15.1) | 3.1 (1.0–10.2) | 5.5 (1.9–15.8) | 0.471 |
| Serum albumin (g l−1) | 35.4±4.5 | 35.2±3.9 | 36.3±6.2 | 0.784 |
| Dysphagia (%) | 13.6 | 39.5** | 30.0 | 0.009 |
| Past history of stroke (%) | 40.0 | 32.6 | 50.0 | 0.540 |
| Ischemic heart disease (%) | 6.2 | 14.0 | 20.0 | 0.242 |
| Congestive heart failure (%) | 16.9 | 20.9 | 30.0 | 0.603 |
| Chronic kidney disease (%) | 6.2 | 9.3 | 20.0# | 0.339 |
| Diabetes mellitus (%) | 15.5 | 20.9 | 30.0 | 0.490 |
| Hypertension treatment (%) | 18.5 | 34.9* | 20.0 | 0.146 |
| ARB alone (%) | 3.1 | 2.3 | 10.0 | 0.479 |
| ACEI alone (%) | 0 | 2.3 | 0 | 0.422 |
| CaB alone (%) | 4.6 | 11.6 | 10.0 | 0.394 |
| Thiazide alone (%) | 0 | 2.3 | 0 | 0.422 |
| Two or more antihypertensives (%) | 10.8 | 16.3 | 0 | 0.335 |
| ARB with/without others (%) | 10.8 | 14.0 | 0 | 0.452 |
| ACEI with/without others (%) | 1.5 | 7.0 | 10.0 | 0.254 |
| CAB with/without others (%) | 9.2 | 20.9 | 10.0 | 0.212 |
| Thiazide with/without others (%) | 6.2 | 9.3 | 0 | 0.555 |
| SAP+ (%) | 21.5 | 39.5# | 70.0** | 0.004 |
| SAP death (%) | 3.1 | 7.0 | 30.0*! | 0.007 |
Abbreviations: ACEI, angiotensin I-converting enzyme inhibitor; ARB, angiotensin II-receptor blocker; CaB, dihydropiridine calcium-channel blocker; DBP, diastolic blood pressure; SBP, systolic blood pressure.
Results for continuous variables are expressed as mean (95% CI) (range) and compared using one-way ANOVA with Tukey's post-hoc analysis. Discrete variables are reported as percentages and compared by χ2 analysis. Keys as in Table 1. #P<0.10, *P<0.05, **P<0.01 and ***P<0.001 vs. controls. !P<0.10, +P<0.05, ++P<0.01 and +++P<0.001 vs. moderate hypertensives.
Association of SAP with hypertensive state on admission after adjustment for potential confounders
| P | |||
|---|---|---|---|
| Controls | 14 | 1.0 | |
| Moderate hypertensives | 17 | 2.36 (0.76–7.29) | 0.136 |
| Severe hypertensives | 7 | 2.83 (1.14–7.05) | 0.025 |
Abbreviation: CI, confidence interval.
Adjusted for age, sex, Glasgow Coma Scale score, WBC, log(serum C-reactive protein) and dysphagia.
Reference group.
Association of SAP death with hypertensive state on admission after adjustment for potential confounders
| P | |||
|---|---|---|---|
| Controls | 2 | 1.0 | |
| Moderate hypertensives | 3 | 2.57 (0.24–27.3) | 0.434 |
| Severe hypertensives | 3 | 5.20 (1.01–26.8) | 0.049 |
Abbreviation: CI, confidence interval.
Adjusted for age, sex, Glasgow Coma Scale score, WBC, log(serum C-reactive protein) and dysphagia.
Reference group.
Association of poor outcome (in-hospital death or artificial feeding at discharge) with hypertensive state on admission after adjustment for potential confounders
| P | |||
|---|---|---|---|
| Controls | 9 | 1.0 | |
| Moderate hypertensives | 14 | 2.06 (0.26–16.3) | 0.491 |
| Severe hypertensives | 5 | 6.84 (1.32–35.4) | 0.022 |
Abbreviation: CI, confidence interval.
Adjusted for age, sex, Glasgow Coma Scale score, white blood cell count, log(serum C-reactive protein) and dysphagia.
Reference group.